fbpx Yourgene Health plc - Home
previous arrow
next arrow

Innovation and creativity are two pillars at the heart of technological and scientific advances. The instrumental role they play has been recognised by the United Nations (UNN), who have designated a special day to raise awareness of the importance of innovation in culture and economic growth worldwide: 21st April. World Creativity and Innovation Day (UNN) is a day to encourage people to “think outside the box”, find new perspectives which push personal growth, identify different talents and cultures, and share ideas. The ultimate goal of the day is to  promote economic and knowledge growth, as well as expanding job opportunities across different communities. 

The Yourgene Health Innovation Team was formed in April 2020 as part of a restructuring of the research and development department. The brief for the Innovation Team during this first year was to: 

1) Develop externally-focused R&D activities

2) Ensure a solid pipeline of products and services

3) Drive scientific excellence across the company

4) Connect with the clinic 

World Creativity and Innovation Day presents the perfect opportunity for the team to reflect upon their achievements over the last 12 months in relation to these objectives. In doing so, these reflections highlight the crucial role their work has played in the development of Yourgene Health as a business. Some key highlights from the team are discussed below:

1) Develop externally-focussed R&D activities

The team have expanded their network, allowing them to facilitate potential licencing deals, collaborations and key partnerships. One key collaboration established was with a team of advisors at Health Innovation Manchester who bring expertise across all aspects of working with the NHS and innovation from trials, evaluation and market need analysis to procurement and adoption. Similarly, engaging with MMPathIC and NIHR enabled the team to access local expertise, IP information and clinical sample collections while ensuring we are immersed in the local innovation ecosystem alongside our local universities. The team also currently work with Imperial College London’s Industrial Partnership and Commercialisation teams to explore licensing opportunities in the coming year. The team recognises the importance of horizon scanning and keeping up-to-date with technological advances. An example of this practice in action is the production of bi-weekly reviews of the In Part Weekly digest and Genome Web. 

2) Ensure a solid pipeline of products

Over the last year, the innovation team has provided an assessment of several new technologies outside the companies’ current scope, including new amplification approaches such as LAMP (Loop-mediated amplification). Innovation was also instrumental in the development of the Clarigene™ SARS-CoV-2 product. Yourgene Health began development of the product in early 2020 in response to the COVID-19 pandemic. The team were able to reduce the workflow steps and mitigate extraction material supply chain issues, and have assessed different improvements previously addressed in the market. The work culminated in a methods publication focusing on reliability based on a proprietary internal control primers within the workflow, with the overall net result being to reduce false-negatives. You can read more about this here.

3) Drive scientific excellence

The team lead the culture of innovation through a scientific excellence series, introducing guest speakers and involving members across the company to ensure they are kept up to date with advances in technology. The hugely successful scientific excellence club (SEC) provides an opportunity to review scientific advances and evaluate emerging technologies to maintain scientific credibility and support professional development. SEC has been shown to play an important part in professional development as it improves skills in leadership, debating and critical appraisal.

4) Connect with the clinic

A big focus for the team over the last 12 months has been to connect more with Yourgene Health key stakeholders and opinion leaders and to use these relationships to improve the products and services we deliver. The results of building these relationships have included a joint publication with 6 NHS trusts, which outlined results and findings from the IONA® Twin Study. The paper concluded that NIPT is effective and safe at detecting Down’s Syndrome in twin pregnancies. This paper established the presence of Yourgene Health in the scientific media, demonstrating our commitment to partnering with the clinical community to the benefit of patients.

Yourgene Health team has also made an impact in the public health space, both in the UK and wider Europe. The Elucigene® DPYD assay is a pioneering example pharmacogenomics being truly integrated within routine care. The test is now being used across the NHS in both England and Wales to test all eligible oncology patients. DPYD screening has also been recommended in Belgium and Germany, where our pre-existing commercial background has allowed us to contribute to the market supply. 

From Yourgene Health, and particularly from the Innovation Team, we would like to thank everyone who has been involved in the innovation process within the Company, engaging with Dragons Den, Gateway submissions, Scientific Review Group, Steering Committees and to the overall growth of the business. We are looking forward to the coming year and hope to build on our innovation successes and continue to develop innovation within Yourgene Health. Happy Innovation Day!

  • Ranger® Revolution - LightBench® Detect is here! - 20 June 2022 +

    Ranger® Revolution - LightBench® Detect is Here!

    The wait is over! Yourgene Health are proud to today reveal the Ranger® Revolution in the form of the LightBench® Detect; the latest addition to our Ranger® Technology portfolio. We’ve worked closely with our clinical laboratory partners to develop a size selection instrument that is optimised for improving the performance of liquid biopsy workflows, most notably non-invasive prenatal testing (NIPT). The LightBench® Detect addresses a pressing need for NIPT

    Read More
  • Collaboration to Perform: Yourgene Microdeletions Plugin Accelerator - 24 May 2022 +

    Yourgene Health is today unveiling the Yourgene Microdeletions Plugin Accelerator phase, following a successful pilot project with LifeStrands Genomics. This Accelerator represents a new era in Yourgene’s approach to delivery of NIPT testing solutions, with a focus on ‘Collaboration to Perform’. Working as a partnership, rather than the traditional laboratory/manufacturer relationship, represents a shared commitment to ensuring high-quality and performance-driven testing, ultimately delivering better outcomes for patients.

    The Plugin has been designed for use with

    Read More
  • Exclusion criteria for NIPT explained - 15 February 2022 +

    The IONA ® test is a non-invasive prenatal test (NIPT) for pregnant women which estimates the risk of a fetus having Down’s syndrome (Trisomy 21), Edwards’ syndrome (Trisomy 18) and Patau’s syndrome (Trisomy 13). The test is performed by analysing cell-free placental-fetal DNA from a maternal blood sample. The test is suitable for women who are at least 10 weeks pregnant, prior to ten weeks there is a risk that there would be insufficient placental-fetal cell

    Read More
  • International Women and Girls in Science Day 2022 +

    Here at Yourgene Health, we are very proud that a large proportion of our genomic technologies and services business, including senior leadership and laboratory managers, are powerful women. We believe it is important to showcase the impressive range of talent we are lucky to have, including our women and girls in science.

    In light of the International Day of Women and Girls in Science, we would like to place a spotlight on a few members

    Read More
  • New Year, New Regulations - 19 January 2022 +

    The ‘New Year's resolution’ is a tradition almost all of us are familiar with, in which a person resolves to accomplish a personal goal, continue good habits or change undesirable ones all with the intention of self-improvement. A study of over 800 million activity data points on the exercise platform Strava found that today, January 19th, is the most common day for a New Year’s resolution to be abandoned ( 1 ). If you are reading this

    Read More
  • Behind the scenes: Adapting diagnostic services during a pandemic - 11 November 2021 +

    The diagnostic testing business has always been dynamic and opportunistic , but nothing could have stretched the definition of these 2 words like a pandemic.

    Since the launch of Yourgene Genomic Services 6 months into this global pandemic – born from a legacy, well established NIPT service laboratory, a modest acquisition, and an unprecedented national genomic testing demand, we have vastly expanded our testing capacity by converting every spare inch of underutilised office space created by remote

    Read More
  • Overprescribing within the NHS - 02 November 2021 +

    “Good for you, good for us but is it good for everybody?”
    Overprescribing within the NHS – October 2021

    The NHS is currently the 5th largest global employer; with over 1.3m employees and receiving around 10% of the UK Government’s annual spending. It is estimated that the NHS deals with 336 million ‘patient visits’ per year, - many of whom will receive some form of at least one ‘prescription’ per visit and at a current charge in

    Read More
  • The role genomics plays in relationships - 18 August 2021 +

    According to National Today, the website dedicated to highlighting every day celebrations and holidays, August 18 th is ‘National Couple’s Day’ – a day to celebrate the important relationships in life. Whilst not an official holiday or observance in any country, the clinical team at Yourgene Health wanted to use this opportunity to reflect upon the pivotal role that genomics plays in relationships across the world.

    Earlier this year a study, published in Nature Human Behaviour,

    Read More
  • NIPT for Sex Chromosome Aneuploidies and Autosomal Aneuploidies. A Q&A with Dr Greg Fitzgibbon - 26 May 2021 +

    Yourgene Health has recently launched IONA ® Care , an advanced prenatal screening test that performs whole-genome analysis to measure the likelihood that a pregnant woman is carrying a fetus with one the most common trisomies (trisomy 21, 18 and 13), any other Autosomal Aneuploidy (AA) or a Sex Chromosome Aneuploidy (SCA). IONA ® Care is available from the Yourgene Genomic Services laboratory in Manchester, UK. The test is available as a menu, enabling pregnant women, their families

    Read More
  • COVID-19 testing and the need for regulation - 6 May 2021 +

    The COVID-19 pandemic presented huge challenges worldwide. In response to the unprecedented need for COVID-19 PCR testing, the UK government set up a new network of Lighthouse laboratories across the country to provide the required capacity for testing thousands of samples each day. These laboratories proved a vital part of the test and trace strategy but were also under immense pressure to meet their targets and, following an investigation by Panorama , it was found that

    Read More
  • Yourgene on World Creativity and Innovation Day 2021 - 21 April 2021 +

    Innovation and creativity are two pillars at the heart of technological and scientific advances. The instrumental role they play has been recognised by the United Nations (UNN), who have designated a special day to raise awareness of the importance of innovation in culture and economic growth worldwide: 21st April. World Creativity and Innovation Day (UNN) is a day to encourage people to “think outside the box”, find new perspectives which push personal growth, identify different

    Read More
  • The IONA® test recommended for twin pregnancies screening for Down’s syndrome - 7 April 2021 +

    In recent years, fertility treatments and the fact women are having babies later has made multiple births more common. In 2016, around 12,000 sets of twins and about 190 sets of triplets or more were born in the UK. That means about 1 in every 65 births in the UK today are twins, triplets or more. 1 Extensive studies have been carried out for cell-free DNA (cfDNA) testing in singleton pregnancies with sample numbers into

    Read More
  • Blood clots, inherited thrombophilia and COVID-19 - 25 March 2021 +

    Recent reports in the media from a collection of European countries suggest that there may be cause for concern with regards to the Oxford AstraZeneca COVID-19 vaccine and abnormal blood clotting. According to Norway’s medicines agency (NoMA), four new cases of “serious blood clotting in adults” have been identified following a recent review (1). Austria have suspended the use of one particular batch of the vaccine after two events, including an individual diagnosed with multiple

    Read More
  • COVID-19 strains - what are they and why do they matter? A Q&A with Dr Michael Risley - 28 January 2021 +

    The COVID-19 pandemic, also known as the coronavirus pandemic, is an ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the beginning of the global COVID-19 outbreak, the diagnostic and research community has undertaken an unprecedented effort to understand how best to manage, eradicate and prevent the disease. In recent months we have seen the rollout of ambitious vaccination schedules worldwide, as well as the strengthening of

    Read More
  • So much to be proud of! - 23 December 2020 +

    As many have already said and written, this year has been like none other. This has been especially true for conferences and exhibitions. Every year, the commercial team at Yourgene look forward to exhibiting at various conferences globally. It’s a chance to meet our partners and customers, as well as form new relationships. With the COVID-19 pandemic none of this was possible, so when we heard that the Taiwan Healthcare Expo was still going ahead,

    Read More
  • 1
  • 2